Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710383 | 0.91 | CNR1 (0.45) | HDAC1HDAC2HDAC6CNR1CNR2 | |
| SCHEMBL709821 | 0.90 | CHRM1 (0.46) | HDAC1HDAC2HDAC6CNR1CNR2 | |
| SCHEMBL711445 | 0.89 | PLA2G2A (0.44) | HDAC1HDAC2HDAC6CNR1CNR2 | |
| SCHEMBL711475 | 0.82 | PLA2G2A (0.39) | HDAC1HDAC2HDAC6CNR1CNR2 | |
| SCHEMBL13356746 | 0.81 | SLC6A2 (0.46) | HDAC1HDAC2HDAC6CNR1CNR2 | |
| SCHEMBL916292 | 0.80 | P2RX3 (0.38) | ALDH1A1GAA | |
| SCHEMBL711655 | 0.79 | TP53 (0.38) | HDAC1HDAC2HDAC6CNR1CNR2 | |
| SCHEMBL709121 | 0.79 | P2RX7 (0.44) | CNR1CNR2LMNAALDH1A1PLA2G2A | |
| SCHEMBL916153 | 0.78 | POLB (0.43) | CNR2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL711222 | 0.76 | P2RX7 (0.38) | HDAC1HDAC2HDAC6CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124647-B2 | Non-steroidal androgens compounds | N.V. ORGANON (NL) | 2012-02-28 | — | — | US | disclosed |
| US-8124647-B2 | Non-steroidal androgens compounds | N.V. ORGANON (NL) | 2012-02-28 | — | — | US | disclosed |
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | MERCK SHARP & DOHME B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | MERCK SHARP & DOHME B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-7795280-B2 | Indoles useful in the treatment of androgen-receptor related diseases | N.V. ORGANON (NL) | 2010-09-14 | — | — | US | disclosed |
| US-7795280-B2 | Indoles useful in the treatment of androgen-receptor related diseases | N.V. ORGANON (NL) | 2010-09-14 | — | — | US | disclosed |
| US-7795280-B2 | Indoles useful in the treatment of androgen-receptor related diseases | N.V. ORGANON (NL) | 2010-09-14 | — | — | US | disclosed |
| EP-1585727-B1 | INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES | ORGANON NV (NL) | 2010-05-26 | — | — | EP | disclosed |
| EP-1585727-B1 | INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES | ORGANON NV (NL) | 2010-05-26 | — | — | EP | disclosed |
| US-20060128722-A1 | Indoles useful in the treatment of androgen-receptor related diseases | AKZO NOBEL N.V. (NL) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065768-A1 | NON-STEROIDAL ANDROGENS COMPOUNDS | AR, NR5A1, SHBG | HDAC1 469/4885HDAC2 1285/4885HDAC6 787/4885 |
| US-20060128722-A1 | Indoles useful in the treatment of androgen-receptor related diseases | AR, NR5A1, SHBG | HDAC1 1025/4885HDAC2 1646/4885HDAC6 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.